Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation

NCT02428296 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

NIH

Sponsor class

Conditions

PIK3CA-Related Overgrowth Spectrum (PROS)
Growth Disorder
Genetics

Interventions

DRUG: Sirolimus

Sponsor

National Human Genome Research Institute (NHGRI)